/ /

  • linkedin
  • Increase Font
  • Sharebar

    Sustained drug delivery moving toward clinical use



    Zordera is an early stage university start-up. The goal is to commercialize novel thin-film polymer fabrication for glaucoma and other ophthalmic conditions.

    “In glaucoma, we have great drugs and patients are using them 50% of the time, maybe less,” said Co-Founder Robert Bhisitkul, MD, PhD, professor of clinical ophthalmology at the University of California, San Francisco. “We are creating tiny biodegradable films that I can inject in the office that give linear drug release over an extended period.”

    The new polymer uses pores matched to the drug to allow diffusion at a controlled rate. Results in animal trials show no evidence of cataracts, endophthalmitis, glaucoma, retinal degradation, or uveitis.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results